Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120623 | 0.83 | HSD17B10 (0.56) | ELANEASAH1SLC22A12TFPI2L3MBTL1 | |
| SCHEMBL27780009 | 0.83 | SLC22A12 (0.52) | ELANEASAH1SLC22A12TFPI2L3MBTL1 | |
| SCHEMBL29754118 | 0.82 | ELANE (0.49) | ELANEASAH1SLC22A12TFPI2KMO | |
| SCHEMBL2363023 | 0.82 | ELANE (0.49) | ELANEASAH1SLC22A12TFPI2KMO | |
| SCHEMBL1087434 | 0.80 | CHEK1 (0.60) | ELANEASAH1SLC22A12TFPI2L3MBTL1 | |
| SCHEMBL10396389 | 0.80 | TFPI2 (0.47) | ELANEASAH1SLC22A12TFPI2PKM | |
| SCHEMBL14193258 | 0.80 | ASAH1 (0.53) | ELANEASAH1SLC22A12TFPI2L3MBTL1 | |
| SCHEMBL4423022 | 0.80 | SLC22A12 (0.55) | ELANEASAH1SLC22A12TFPI2L3MBTL1 | |
| SCHEMBL28331603 | 0.79 | SLC22A12 (0.46) | ELANEASAH1SLC22A12TFPI2L3MBTL1 | |
| SCHEMBL260982 | 0.78 | SLC22A12 (0.54) | ELANEASAH1SLC22A12TFPI2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036679-A | Preparation method and application of indazole carboxylic acid | 广东大丰植保科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-31 | — | — | US | disclosed |
| EP-4326719-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-02-28 | — | — | EP | disclosed |
| CN-104640847-B | Novel Renin Inhibitors | 上海医药集团股份有限公司 | 2019-10-15 | — | — | CN | disclosed |
| CN-110003169-A | GPR40 receptor agonist, method for preparing same, and pharmaceutical composition containing same as active ingredient | 株式会社LG化学 | 2019-07-12 | — | — | CN | disclosed |
| US-9540362-B2 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG LIFE SCIENCES LTD. (KR) | 2017-01-10 | — | — | US | disclosed |
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2015-12-31 | — | — | US | disclosed |
| EP-2958913-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG Life Sciences Ltd. (KR) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014129796-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2014-08-28 | — | — | WO | disclosed |
| CN-104011027-A | Use of lonidamine analogs for fertility regulation | UNIV KANSAS | 2014-08-27 | — | — | CN | disclosed |
| WO-2009106980-A2 | INDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| CN-1863777-A | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2006-11-15 | — | — | CN | disclosed |
| EP-0939757-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Dupont Pharmaceuticals Company (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1997023480-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | S1PR1, S1PR2, S1PR5 | ELANE 3333/4885ASAH1 112/4885SLC22A12 3896/4885 |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA1 | ELANE 3667/4885ASAH1 1472/4885SLC22A12 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.